Comparison of Long-Term Clinical Outcomes of CHOP Chemotherapy between Japanese Patients with Nodal Peripheral T-Cell Lymphomas and Those with Diffuse Large B-Cell Lymphoma in the Study Group of the Tohoku Hematology Forum

Akagi, Tomoaki; Takahashi, Naoto; Yamaguchi, Kouhei; Ishizawa, Kenichi; Murai, Kazunori; Tajima, Katsushi; Ikeda, Kazuhiko; Kameoka, Yoshihiro; Kameoka, Junnichi; Ito, Shigeki; Kato, Yuichi; Noji, Hideyoshi; Shichishima, Tsutomu; Itoh, Jugoh; Ichinohasama, Ryo; Harigae, Hideo; Ishida, Yoshiteru; Sawada, Kenichi

doi:10.3960/jslrt.51.29

Cited by 7 publications

(5 citation statements)

References 27 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increasing number of research studies suggest that etoposide has been used in intensive chemotherapy regimens, such as cisplatin, etoposide, gemcitabine, and solumedrol (PEGS), and L-asparaginase and etoposide (SMILE) for PTCL 25,26. Indeed, as a standard therapy for PTCL, most patients treated with CHOP will achieve a CR ranging from 31%–69%27 or a CR + PR of 48% 28. Notably, a study has demonstrated that the ORR and CR for evaluable non-Hodgkin’s lymphoma patients was significantly increased in CHOPE group compared to CHOP group (ORR: 82.5% vs 62.5%; CR: 52.5% vs 45%), respectively 29.…”

Section: Discussionmentioning

confidence: 99%

<p>Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis</p>

Deng¹,

Lin²,

Shen³

et al. 2019

OTT

View full text Add to dashboard Cite

Objective To compare cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and CHOP plus etoposide (CHOPE) with regard to outcomes including efficacy and safety for patients with peripheral T-cell lymphoma (PTCL). Methods Relevant literature was searched using PubMed, Embase, Wanfang, and CNKI for eligible trials comparing CHOP with CHOPE for treatment of PTCL. The following outcomes of PTCL patients were considered: complete response (CR), partial response (PR), overall response rate (ORR), and adverse events (AEs; grade >3). Risk ratios (RRs) were appropriately derived from fixed-effects or random-effects models. Results A total of five prospective or retrospective articles with 1,560 patients were elected for the meta-analysis. There were no significant differences in CR (RR =1.11, 95% CI: 0.73–1.67, P =0.632), PR (RR =1.40, 95% CI: 0.52–3.76, P =0.504), and ORR (RR =1.25, 95% CI: 0.93–1.69, P =0.146) between the CHOP and CHOPE groups. However, AEs including anemia (RR =1.69, 95% CI: 1.33–2.16, P <0.001) and thrombocytopenia (RR =1.43, 95% CI: 1.15–1.77, P =0.001) were significantly increased in CHOPE group compared to that in CHOP group. Conclusion Meta-analysis suggested that there were no differences in therapeutic effect for patients with PTCL between CHOP and CHOPE groups with regards to CR, PR, and ORR, whereas the CHOPE group had significantly increased AEs (anemia and thrombocytopenia) compared to CHOP group.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis</p>

Deng¹,

Lin²,

Shen³

et al. 2019

OTT

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…The peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of mature T-cell lymphomas that are usually characterized by aggressive clinical behavior, and a paucity of salvage therapies, especially in contrast to their B-cell counterparts [Akagi et al 2011;Puig et al 2013;Hamadani et al 2014]. The outcome of frontline chemotherapy regimens has been disappointing, with reported long-term survival of only 20-30% [Hamadani et al 2014].…”

Section: Introductionmentioning

confidence: 99%

Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review

Sawas

Radeski²,

O’Connor

2015

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Peripheral T-cell lymphoma (PTCL) is a disease with poor prognosis and limited treatment options. Recent advances in cancer biology suggest that PTCL may be characterized by gross epigenetic dysregulation, which may help explain its sensitivity to histone deacetylase (HDAC) inhibitors. HDAC inhibitors have demonstrated significant activity in T-cell neoplasms and recently, the BELIEF trial evaluated belinostat leading to its approval in the US. This review discusses the development of belinostat, its mechanism of action, pivotal clinical trials, drug toxicity and its recent approval for patients with relapsed or refractory PTCL. Key clinical trials covered include phase I/II evaluation of belinostat in hematologic malignancies, cutaneous T-cell lymphoma (CTCL) and PTCL. In addition, the BELIEF trial in PTCL leading to FDA approval of belinostat is reviewed in detail.

show abstract

“…The majority of PVRL is extranodal, non-Hodgkin, diffuse large B-cell lymphoma (DLBCL) [4]. Although rare, T-cell lymphoma with intraocular involvement has also been reported, usually with poor prognosis [5–7]. …”

Section: Introductionmentioning

confidence: 99%

Molecular Biomarkers for the Diagnosis of Primary Vitreoretinal Lymphoma

Wang

Shen

Wang

et al. 2011

IJMS

102

View full text Add to dashboard Cite

Primary vitreoretinal lymphoma (PVRL) or primary intraocular lymphoma, a subtype of primary central nervous system lymphoma, often masquerades as uveitis. The diagnosis of PVRL requires identification of lymphoma cells inside the eye, which is often challenging due to the frequent necrosis and admixing of PVRL cells with reactive lymphocytes. Therefore, detection of immunoglobulin heavy chain (IgH) and T-cell receptor (TCR) gene rearrangements provide molecular diagnosis of B- and T-cell lymphoma, respectively. We retrospectively evaluated 208 cases with a clinical diagnosis of masquerade syndrome from 1998 to 2010. In 200 cases with molecular analyses using microdissection and polymerase chain reaction, we found that 110 cases had IgH gene rearrangement, 5 cases had TCR gene rearrangement, and 85 cases were negative for these two gene arrangements. The molecular data corroborated the cytopathological diagnoses of PVRL and uveitis in the majority of cases. Cytokine above the detected levels in the specimens were also measured in 80 of the 208 cases. A ratio of vitreous IL-10 to IL-6 greater than 1, suggesting PVRL, was found in 56/80 cases; 53/56 had the correct diagnosis. A ratio less than 1, suggesting uveitis, was found in 24/80 cases; 17/24 correctly confirmed the diagnosis. Moreover, the molecular data corresponded well with the clinical course of the diseases. The sensitivity and specificity of these molecular biomarkers for the diagnosis of PVRL are higher than 95%.

show abstract

Comparison of Long-Term Clinical Outcomes of CHOP Chemotherapy between Japanese Patients with Nodal Peripheral T-Cell Lymphomas and Those with Diffuse Large B-Cell Lymphoma in the Study Group of the Tohoku Hematology Forum

Cited by 7 publications

References 27 publications

<p>Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis</p>

<p>Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis</p>

Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review

Molecular Biomarkers for the Diagnosis of Primary Vitreoretinal Lymphoma

Contact Info

Product

Resources

About